These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30967832)

  • 1. Remnants of Cardinal Symptoms of Parkinson's Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living.
    Goubault E; Nguyen HP; Bogard S; Blanchet PJ; Bézard E; Vincent C; Sarna J; Monchi O; Duval C
    Front Neurol; 2019; 10():256. PubMed ID: 30967832
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardinal Motor Features of Parkinson's Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia.
    Goubault E; Nguyen HP; Bogard S; Blanchet PJ; Bézard E; Vincent C; Langlois M; Duval C
    J Parkinsons Dis; 2018; 8(2):323-331. PubMed ID: 29843253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson's Disease.
    Goubault E; Bogard S; Blanchet PJ; Bézard E; Vincent C; Martino D; Sarna J; Monchi O; Duval C
    Tremor Other Hyperkinet Mov (N Y); 2020 Jul; 10():20. PubMed ID: 32775034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-task interference during hand dexterity is a predictor for activities of daily living performance in Parkinson's disease.
    Acaröz Candan S; Özcan TŞ
    Parkinsonism Relat Disord; 2019 Sep; 66():100-104. PubMed ID: 31324554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Experience in Early-Stage Parkinson's Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment.
    Morel T; Cleanthous S; Andrejack J; Barker RA; Blavat G; Brooks W; Burns P; Cano S; Gallagher C; Gosden L; Siu C; Slagle AF; Trenam K; Boroojerdi B; Ratcliffe N; Schroeder K
    Neurol Ther; 2022 Sep; 11(3):1319-1340. PubMed ID: 35778541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-induced dyskinesia in Parkinson's disease: Insights from cross-cohort prognostic analysis using machine learning.
    Loo RTJ; Tsurkalenko O; Klucken J; Mangone G; Khoury F; Vidailhet M; Corvol JC; Krüger R; Glaab E;
    Parkinsonism Relat Disord; 2024 Jul; 126():107054. PubMed ID: 38991633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors of levodopa-induced dyskinesia in Parkinson's disease: results from the PPMI cohort.
    Eusebi P; Romoli M; Paoletti FP; Tambasco N; Calabresi P; Parnetti L
    NPJ Parkinsons Dis; 2018; 4():33. PubMed ID: 30480086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa.
    Schaafsma JD; Giladi N; Balash Y; Bartels AL; Gurevich T; Hausdorff JM
    J Neurol Sci; 2003 Aug; 212(1-2):47-53. PubMed ID: 12809998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can We Predict the Motor Performance of Patients With Parkinson's Disease Based on Their Symptomatology?
    Lebel K; Duval C; Goubault E; Bogard S; Blanchet PJ
    Front Bioeng Biotechnol; 2020; 8():189. PubMed ID: 32266228
    [No Abstract]   [Full Text] [Related]  

  • 12. Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease.
    Hoff JI; van den Plas AA; Wagemans EA; van Hilten JJ
    Mov Disord; 2001 Jan; 16(1):58-61. PubMed ID: 11215593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Informant Perceptions of the Cause of Activities of Daily Living Difficulties in Parkinson's Disease.
    Benge JF; Balsis S
    Clin Neuropsychol; 2016; 30(1):82-94. PubMed ID: 26838807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward objective monitoring of Parkinson's disease motor symptoms using a wearable device: wearability and performance evaluation of PDMonitor
    Antonini A; Reichmann H; Gentile G; Garon M; Tedesco C; Frank A; Falkenburger B; Konitsiotis S; Tsamis K; Rigas G; Kostikis N; Ntanis A; Pattichis C
    Front Neurol; 2023; 14():1080752. PubMed ID: 37260606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyskinesia-induced postural instability in Parkinson's disease.
    Armand S; Landis T; Sztajzel R; Burkhard PR
    Parkinsonism Relat Disord; 2009 Jun; 15(5):359-64. PubMed ID: 18851925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia.
    Vegas-Suarez S; Paredes-Rodriguez E; Aristieta A; Lafuente JV; Miguelez C; Ugedo L
    Int Rev Neurobiol; 2019; 146():259-279. PubMed ID: 31349930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing Objective and Subjective Measures of Parkinson's Disease Using the Parkinson's KinetiGraph.
    Knudson M; Thomsen TH; Kjaer TW
    Front Neurol; 2020; 11():570833. PubMed ID: 33250843
    [No Abstract]   [Full Text] [Related]  

  • 18. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
    Zesiewicz TA; Sullivan KL; Hauser RA
    Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responsiveness of impairments and disabilities in Parkinson's disease.
    Visser M; Marinus J; Stiggelbout AM; van Hilten JJ
    Parkinsonism Relat Disord; 2006 Jun; 12(5):314-8. PubMed ID: 16621658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.